CANSINOBIO News

Cansino Biotech (6185.HK): Influenza vaccine drives quarterly profit recovery and multiple pipelines to build future growth points

first shanghaiNov 22 00:00

Cansino (688185): Successful sales of influenza vaccine turned a loss into a profit in the third quarter

haitong secNov 18 20:42

Cansino (688185): Improving operating efficiency and promoting sales of fluent products smoothly

海通證券Sep 13 08:41

Cansino Biotech (6185.HK): MCV series achieved significant improvements in continuous volume operation in the first half of the year

Sep 1 00:00

Cansino (688185): Performance is in line with expectations PCV13 will soon be approved

Aug 31 11:26

Cansino (688185) Research Report: First coverage of conventional vaccines, initial results in cost reduction and efficiency

Jun 2 00:00

Cansino (688185): Continued growth of conventional vaccines, initial results in cost reduction and efficiency

May 31 14:46

Cansino (688185): MCv4 continuous release cost control has seen initial results

May 6 15:36

Cansino Biotech (6185.HK): The MCV series's continuous volume performance throughout the year affects clear and light progress

Apr 3 14:21

Cansino (688185): Performance is in line with expectations, MCV4 sales performance is outstanding

Mar 29 18:46

Cansino (688185): Looking forward to the release of the MCv4 vaccine after COVID-19 disturbances have been cleared

Mar 29 00:00

Changes in Hong Kong stocks | Cansino Biotech (06185) fell more than 4% at the end of the session, it was revealed that Kexon's COVID-19 vaccine was discontinued, and Lyon drastically lowered the target price of Cansino

Zhitong FinanceJan 12 15:51

CITIC Lyon: Maintaining Cansino Biotech's (06185) “Buy” Rating Target Price Dramatically Reduced to HK$29

Zhitong FinanceJan 12 14:37

Cansino (688185): Release of quadrivalent influenza vaccine, inventory impairment clearance, focus on conventional vaccine product lines

Dec 28, 2023 00:00

Cansino (688185): MRNA technology approved by internationally renowned pharmaceutical companies to fully launch cooperative non-COVID-19 vaccine pipelines

華鑫證券Aug 10, 2023 00:00

Concino (688185): Net profit is in line with expectations, focus on MCV4 volume and pipeline progress

中金公司Mar 28, 2023 15:13

Major bank ratings | UBS: Inhaled COVID-19 vaccine is gradually becoming mainstream, reaffirming Concinol-B's “buy” rating

Gelonghui FinanceOct 26, 2022 16:00

Cansino (688185): Overseas competition for COVID-19 vaccines continues to intensify, waiting for MCV2/4 products to be released

中信證券Sep 7, 2022 23:50

Cansino (688185): The COVID-19 vaccine is under pressure, MCV4 has officially entered the commercialization stage

中金公司Aug 30, 2022 00:00

Kangcino Biotech (6185.HK): Impairment affects current performance, MCV series release can be expected

中信建投證券Aug 29, 2022 12:56